Venture-backed orphan drug accelerator Cydan Development Inc. is taking on sickle cell disease (SCD) through the launch of its second new company, Imara Inc. Financed with a $31 million series A round from Cydan's syndicate, Imara will soon file an investigational new drug application for its phosphodiesterase 9 (PDE9) inhibitor, IMR-687.